Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The RETIRE Trial: A Randomized Phase 2 Trial of Adoptive Therapy With Treg Adoptive Cell Transfer (TRACT) To Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT06552169 is registered in ClinicalTrials.gov with Singulera Therapeutics Inc. as lead sponsor.

NCT NCT06552169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06552169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The RETIRE Trial: A Randomized Phase 2 Trial of Adoptive Therapy With Treg Adoptive Cell Transfer (TRACT) To Prevent Rejection in Living Donor Kidney Transplant Recipients
Lead sponsor
Singulera Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 13, 2025
Completion date
December 31, 2031
Enrollment
34 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation